Pedmark significantly reduces cisplatin-induced hearing loss in pediatric and AYA patients with non-metastatic solid tumors. The trial confirmed Pedmark's non-interference with cisplatin's antitumor ...

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. Two of six patients experienced dose-limiting neutropenia at a dose of paclitaxel 140 mg/m2/96 hours and cisplatin ...

Cisplatin-induced hearing loss can be reduced by the delayed administration of the otoprotectant sodium thiosulfate (Pedmark, Fennec Pharmaceuticals). The finding comes from a trial conducted in 101 ...

Toxicity was evaluated before each treatment cycle as described in the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3.0. In cases of grade 3/4 neutropenia of over 5 days ...

The odds of cisplatin-induced acute kidney injury decreased with prophylactic administration of intravenous magnesium. Infusing prophylactic magnesium before initiating intravenous cisplatin for ...

Renewed interest in hepatic arterial chemotherapy infusion pumps may be on the horizon, given promising overall survival findings in patients with advanced, unresectable cholangiocarcinoma. Dutch ...